Detalhe da pesquisa
1.
Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Oncology
; 94(5): 274-280, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29471300
2.
A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma.
Oncology
; 93(6): 401-405, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28869931
3.
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Clin Lymphoma Myeloma Leuk
; 18(1): 58-64, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29056470